L.E.L. Hendriks

Dingemans, A. M. C., Opitz, I., Brunelli, A., Remon, J., Hendriks, L. E. L., Edwards, J., Faivre-Finn, C., Reguart, N., Smit, E. F., Levy, A., Sanchez-Lorente, D., Trujillo, J. C., Filippi, A. R., Stathopoulos, K., Blum, T. G., Guckenberger, M., Popat, S., De Angelis, R., Hofman, P., ... Berghmans, T. (2026). Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration. The Lancet Respiratory medicine, 14(5), 10. https://doi.org/10.1016/S2213-2600(26)00051-2

Bartolomeo, V., Jongbloed, M., Huijs, J. W. J., Filippi, A. R., van den Borne, B. E. E. M., Pitz, C., Gietema, H., Degens, J., Soud, M. Y.-E., Steens, M., Dursun, S., van Geffen, W. H., de Boer, P., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2026). Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment. Lung Cancer, 214, Article 109337. https://doi.org/10.1016/j.lungcan.2026.109337

de Ruiter, J. C., van der Noort, V., van Diessen, J. N. A., Smit, E. F., Damhuis, R. A. M., Hartemink, K. J., Yang, Z. L., van der Woude, L., van den Wildenberg, F. J. H., Wijsman, R., Wener, R. R., van der Wekken, A. J., de Wee, E. M., van de Wauwer, C., van der Voort van Zyp, N. C. M. G., Verhoeff, J. J. C., Verhagen, A. F. T. M., Verbruggen, L., Verbogt, N. P. A., ... ESLUNG group (2026). Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics. British Journal of Cancer, 134(6), 893-902. https://doi.org/10.1038/s41416-025-03332-7

Huang, Y., Wei, Z., Ye, G., Cui, Y., Li, C., Wu, G., Yang, W., Zhang, B., Zhang, Z., Jiang, Y., Hendriks, L. E. L., Wee, L., De Ruysscher, D., Dekker, A., Shi, L., Liu, Z., He, B., & Shi, Z. (2026). Automated CT-derived body composition predicts pathologic response to neoadjuvant immunotherapy in non–small cell lung cancer. Cancer Letters, 640, Article 218229. https://doi.org/10.1016/j.canlet.2025.218229

Angrisani, A., Kirova, Y., Abravan, A., Becherini, C., Benavente, S., Castelo-Branco, L., Chalmers, A. J., Christ, S. M., Deutsch, E., Filippi, A. R., Hendriks, L. E. L., Zolcsak, Z., Illidge, T., Rimner, A., Herrera, F., & De Ruysscher, D. (2026). Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy. The Lancet Oncology, 27(3), e150-e159. https://doi.org/10.1016/S1470-2045(25)00660-6

Noordhof, A., Asmara, O. D., de Jong, K., Gijtenbeek, R. G., Huitema, Y. M., van Vollenhoven, F. H., Venmans, B. J., Hendriks, L., & van Geffen, W. H. (2026). KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation. Cochrane Database of Systematic Reviews, 2, Article CD016054. https://doi.org/10.1002/14651858.CD016054

van Dijk, E. J., Smeenk, M. M., Bensch, F., Sadowksa, A. M., Verschueren, M. V., Verhaert, M., Llobell, A., Suzuki, Y., Liew, D. F. L., Takeji, A., Maria, A. T. J., Peters, B. J. M., Garcia Morillo, J. S., Chatzidionysiou, K., Lidar, M., van der Hout, E. C., Aspeslagh, S., Herder, G. J. M., van de Garde, E. M. W., ... Verheijden, R. J. (2026). Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer. ESMO Open, 11(2), Article 106052. https://doi.org/10.1016/j.esmoop.2025.106052

Jongbloed, M., Damhuis, R. A. M., Van Geffen, W. H., de Boer, P., Huijs, J. W. J., Dursun, S., Degens, J., van den Borne, B. E. E. M., Soud, M. Y. E., Steens, M., Pitz, C., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2026). Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis. Lung Cancer, 212, Article 108889. https://doi.org/10.1016/j.lungcan.2025.108889

Cheo, S. W., Li, M. S. C., Huang, D. D. R., Saw, S. P. L., Hendriks, L. E. L., Remon, J., Menis, J., Addeo, A., & Voon, P. J. (2026). Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far? Cancer Treatment Reviews, 143, Article 103083. https://doi.org/10.1016/j.ctrv.2025.103083

Ogliari, F. R., Jongbloed, M., Vaes, R. D. W., Houben, R. M. A., Bartolomeo, V., van den Borne, B. E. E. M., Degens, J., Huijs, J. W. J., Pitz, C., Steens, M., Youssef-El Soud, M., Sollini, M., De Ruysscher, D. K. M., Mitea, C., & Hendriks, L. E. L. (2026). Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 1836-1846. https://doi.org/10.1007/s00259-025-07557-9